Central nervous system lymphoma: a morphological MRI study
Jazyk angličtina Země Švédsko Médium print
Typ dokumentu časopisecké články
PubMed
27857050
PII: NEL370416A09
Knihovny.cz E-zdroje
- MeSH
- difuzní magnetická rezonance MeSH
- difúzní velkobuněčný B-lymfom diagnostické zobrazování farmakoterapie imunologie MeSH
- dospělí MeSH
- hormony kůry nadledvin terapeutické užití MeSH
- imunokompetence imunologie MeSH
- imunokompromitovaný pacient imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom diagnostické zobrazování farmakoterapie imunologie MeSH
- magnetická rezonanční tomografie MeSH
- mladý dospělý MeSH
- nádory centrálního nervového systému diagnostické zobrazování farmakoterapie imunologie MeSH
- nádory mozku diagnostické zobrazování farmakoterapie imunologie MeSH
- progrese nemoci MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- hormony kůry nadledvin MeSH
OBJECTIVES: The aim of the present study was to evaluate morphological MRI findings in histologically-proven central nervous system lymphoma (CNSL) at time of their first appearance, and to describe dynamic changes on repeat MRI before the diagnosis was histologically proven. METHODS: We retrospectively evaluated the MRI examinations of 74 patients with histologically-proven CNSL (10 secondary CNSL, 64 primary PCNSL; 10 immunocompromised, 54 immunocompetent). In 43 patients, we evaluated the evolution of CNSL on MRI before the diagnosis was proven. RESULTS: Primary CNSL was typically localized supratentorially (63%), with multiple (59%) or infiltrative (36%) lesions showing diffusion restriction (98%), often (87%) reaching the brain surface. In approximately 50% of patients, meningeal, ependymal or cranial nerve involvement was found. We detected significant differences in enhancement patterns between immunocompromised and immunocompetent patients; non-homogenous enhancement present in 50% of immunocompromised patients. We did not find any significant differences in MRI appearance between primary and secondary CNSL. Regression was evident after corticosteroid treatment in 52% of patients; however, in 16% of cases overall progression was observed. CONCLUSION: CNSL generally presents as an infiltrative lesion or multiple homogenously-enhancing lesions of the brain in contact with the brain surface. Involvement of the corpus callosum, cranial nerves, ependyma or meninges is common. No significant differences between primary and secondary CNSL were detected, however differences in enhancement type between immunocompromised and immunocompetent primary CNSL patients were found. We stress the variability of MRI findings in the course of the disease and also the variable response to corticotherapy.
Secondary central nervous system lymphoma: spectrum of morphological MRI appearances